STOCK TITAN

[Form 4] Health In Tech, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Health In Tech insider Jonathan Del Lockett reported a grant of 7,000 restricted shares of Class A common stock on 08/15/2025. The restricted shares were granted under the Health in Tech Equity Incentive Plan and carry vesting conditions tied to the successful launch and full operation of two specified company programs: 50% of the restricted shares vest monthly over 12 months after the first program is launched, and the remaining 50% vest monthly over 12 months after the second program is launched. Following the reported transaction, Mr. Lockett beneficially owns 93,539 shares (including 22,105 restricted shares and 71,434 unrestricted Class A shares); the filing notes he also holds 165,085 options to purchase Class A common stock that are excluded from the ownership total.

Jonathan Del Lockett di Health In Tech ha comunicato la concessione di 7.000 azioni vincolate di categoria A in data 15/08/2025. Le azioni vincolate sono state assegnate ai sensi del Health in Tech Equity Incentive Plan e prevedono condizioni di maturazione legate al lancio con successo e al pieno funzionamento di due programmi aziendali specifici: il 50% delle azioni vincolate matura mensilmente in 12 mesi a partire dal lancio del primo programma, mentre il restante 50% matura mensilmente in 12 mesi dopo il lancio del secondo programma. Dopo la transazione segnalata, il sig. Lockett detiene beneficiariamente 93.539 azioni (comprese 22.105 azioni vincolate e 71.434 azioni ordinarie di classe A non vincolate); la comunicazione precisa inoltre che è titolare di 165.085 opzioni per l'acquisto di azioni ordinarie di classe A, che sono escluse dal totale di possesso.

Jonathan Del Lockett, de Health In Tech, informó la concesión de 7.000 acciones restringidas de clase A el 15/08/2025. Las acciones restringidas se otorgaron bajo el Health in Tech Equity Incentive Plan y están sujetas a condiciones de consolidación vinculadas al lanzamiento exitoso y al pleno funcionamiento de dos programas concretos de la compañía: el 50% de las acciones restringidas se consolida mensualmente durante 12 meses tras el lanzamiento del primer programa, y el 50% restante se consolida mensualmente durante 12 meses después del lanzamiento del segundo programa. Tras la transacción informada, el Sr. Lockett posee beneficiariamente 93.539 acciones (incluidas 22.105 acciones restringidas y 71.434 acciones ordinarias de clase A sin restricciones); el informe señala que además posee 165.085 opciones para comprar acciones ordinarias de clase A, excluidas del total de propiedad.

Health In Tech의 내부자 Jonathan Del Lockett는 2025년 8월 15일에 클래스 A 보통주 7,000주 제한부 주식을 부여받았다고 보고했습니다. 해당 제한부 주식은 Health in Tech Equity Incentive Plan에 따라 부여되었으며, 특정 회사 프로그램 두 건의 성공적 출시 및 정상 운영에 연동된 베스팅 조건이 적용됩니다: 제한부 주식의 50%는 첫 번째 프로그램 출시 후 12개월 동안 매월 베스트되고, 나머지 50%는 두 번째 프로그램 출시 후 12개월 동안 매월 베스트됩니다. 보고된 거래 이후 Lockett 씨는 총 93,539주를 실질적으로 보유하고 있습니다(제한부 주식 22,105주 및 비제한 클래스 A 보통주 71,434주 포함). 서류에는 또한 클래스 A 보통주를 매수할 수 있는 165,085주의 옵션을 보유하고 있으나 이는 보유 총액에서 제외된다고 명시되어 있습니다.

Jonathan Del Lockett, Insider chez Health In Tech, a déclaré l'attribution de 7 000 actions restreintes de classe A le 15/08/2025. Les actions restreintes ont été accordées en vertu du Health in Tech Equity Incentive Plan et sont soumises à des conditions d'acquisition liées au lancement réussi et au fonctionnement complet de deux programmes spécifiques de la société : 50 % des actions restreintes sont acquises mensuellement sur 12 mois après le lancement du premier programme, et les 50 % restants sont acquis mensuellement sur 12 mois après le lancement du second programme. À la suite de la transaction déclarée, M. Lockett détient de façon bénéficiaire 93 539 actions (dont 22 105 actions restreintes et 71 434 actions ordinaires de classe A non restreintes) ; le dossier précise qu'il détient également 165 085 options d'achat d'actions ordinaires de classe A, exclues du total de détention.

Health In Tech-Insider Jonathan Del Lockett meldete die Gewährung von 7.000 eingeschränkten Aktien der Klasse A am 15.08.2025. Die eingeschränkten Aktien wurden im Rahmen des Health in Tech Equity Incentive Plan gewährt und unterliegen Vesting-Bedingungen, die an den erfolgreichen Start und den vollen Betrieb von zwei bestimmten Unternehmensprogrammen geknüpft sind: 50 % der eingeschränkten Aktien vesten monatlich über 12 Monate nach dem Start des ersten Programms, die verbleibenden 50 % vesten monatlich über 12 Monate nach dem Start des zweiten Programms. Nach der gemeldeten Transaktion besitzt Herr Lockett wirtschaftlich 93.539 Aktien (darunter 22.105 eingeschränkte Aktien und 71.434 unbeschränkte Klasse-A-Stammaktien); in der Meldung wird außerdem vermerkt, dass er 165.085 Optionen zum Kauf von Klasse-A-Stammaktien hält, die vom Besitzgesamtbetrag ausgenommen sind.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Routine executive equity grant with performance-contingent vesting; disclosure aligns with Section 16 reporting requirements.

The Form 4 documents a standard restricted stock award to a named officer under the company equity plan. Vesting is conditional on commercial launch milestones for two company programs, which ties executive incentives directly to product execution. The filing clearly discloses post-transaction beneficial ownership and outstanding option counts. This is a governance-appropriate disclosure and does not, by itself, signal material corporate change.

TL;DR: Grant size is modest relative to outstanding options; vesting structure ties pay to operational milestones.

The award of 7,000 restricted shares aligns executive compensation with milestone delivery by splitting vesting across two program launches. The filing also notes 165,085 options outstanding held by the reporting person, which could represent future potential dilution depending on exercise terms. The disclosed beneficial ownership of 93,539 shares (including 22,105 restricted) provides clear context for current equity stake.

Jonathan Del Lockett di Health In Tech ha comunicato la concessione di 7.000 azioni vincolate di categoria A in data 15/08/2025. Le azioni vincolate sono state assegnate ai sensi del Health in Tech Equity Incentive Plan e prevedono condizioni di maturazione legate al lancio con successo e al pieno funzionamento di due programmi aziendali specifici: il 50% delle azioni vincolate matura mensilmente in 12 mesi a partire dal lancio del primo programma, mentre il restante 50% matura mensilmente in 12 mesi dopo il lancio del secondo programma. Dopo la transazione segnalata, il sig. Lockett detiene beneficiariamente 93.539 azioni (comprese 22.105 azioni vincolate e 71.434 azioni ordinarie di classe A non vincolate); la comunicazione precisa inoltre che è titolare di 165.085 opzioni per l'acquisto di azioni ordinarie di classe A, che sono escluse dal totale di possesso.

Jonathan Del Lockett, de Health In Tech, informó la concesión de 7.000 acciones restringidas de clase A el 15/08/2025. Las acciones restringidas se otorgaron bajo el Health in Tech Equity Incentive Plan y están sujetas a condiciones de consolidación vinculadas al lanzamiento exitoso y al pleno funcionamiento de dos programas concretos de la compañía: el 50% de las acciones restringidas se consolida mensualmente durante 12 meses tras el lanzamiento del primer programa, y el 50% restante se consolida mensualmente durante 12 meses después del lanzamiento del segundo programa. Tras la transacción informada, el Sr. Lockett posee beneficiariamente 93.539 acciones (incluidas 22.105 acciones restringidas y 71.434 acciones ordinarias de clase A sin restricciones); el informe señala que además posee 165.085 opciones para comprar acciones ordinarias de clase A, excluidas del total de propiedad.

Health In Tech의 내부자 Jonathan Del Lockett는 2025년 8월 15일에 클래스 A 보통주 7,000주 제한부 주식을 부여받았다고 보고했습니다. 해당 제한부 주식은 Health in Tech Equity Incentive Plan에 따라 부여되었으며, 특정 회사 프로그램 두 건의 성공적 출시 및 정상 운영에 연동된 베스팅 조건이 적용됩니다: 제한부 주식의 50%는 첫 번째 프로그램 출시 후 12개월 동안 매월 베스트되고, 나머지 50%는 두 번째 프로그램 출시 후 12개월 동안 매월 베스트됩니다. 보고된 거래 이후 Lockett 씨는 총 93,539주를 실질적으로 보유하고 있습니다(제한부 주식 22,105주 및 비제한 클래스 A 보통주 71,434주 포함). 서류에는 또한 클래스 A 보통주를 매수할 수 있는 165,085주의 옵션을 보유하고 있으나 이는 보유 총액에서 제외된다고 명시되어 있습니다.

Jonathan Del Lockett, Insider chez Health In Tech, a déclaré l'attribution de 7 000 actions restreintes de classe A le 15/08/2025. Les actions restreintes ont été accordées en vertu du Health in Tech Equity Incentive Plan et sont soumises à des conditions d'acquisition liées au lancement réussi et au fonctionnement complet de deux programmes spécifiques de la société : 50 % des actions restreintes sont acquises mensuellement sur 12 mois après le lancement du premier programme, et les 50 % restants sont acquis mensuellement sur 12 mois après le lancement du second programme. À la suite de la transaction déclarée, M. Lockett détient de façon bénéficiaire 93 539 actions (dont 22 105 actions restreintes et 71 434 actions ordinaires de classe A non restreintes) ; le dossier précise qu'il détient également 165 085 options d'achat d'actions ordinaires de classe A, exclues du total de détention.

Health In Tech-Insider Jonathan Del Lockett meldete die Gewährung von 7.000 eingeschränkten Aktien der Klasse A am 15.08.2025. Die eingeschränkten Aktien wurden im Rahmen des Health in Tech Equity Incentive Plan gewährt und unterliegen Vesting-Bedingungen, die an den erfolgreichen Start und den vollen Betrieb von zwei bestimmten Unternehmensprogrammen geknüpft sind: 50 % der eingeschränkten Aktien vesten monatlich über 12 Monate nach dem Start des ersten Programms, die verbleibenden 50 % vesten monatlich über 12 Monate nach dem Start des zweiten Programms. Nach der gemeldeten Transaktion besitzt Herr Lockett wirtschaftlich 93.539 Aktien (darunter 22.105 eingeschränkte Aktien und 71.434 unbeschränkte Klasse-A-Stammaktien); in der Meldung wird außerdem vermerkt, dass er 165.085 Optionen zum Kauf von Klasse-A-Stammaktien hält, die vom Besitzgesamtbetrag ausgenommen sind.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Lockett Jonathan Del

(Last) (First) (Middle)
701 S. COLORADO AVE,SUITE 1

(Street)
STUART FL 34994

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Health In Tech, Inc. [ HIT ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Strategy Officer
3. Date of Earliest Transaction (Month/Day/Year)
08/15/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Class A Common Stock 08/15/2025 A 7,000(1) A $0 93,539(2) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represent restricted shares of Class A Common Stock granted to the reporting person pursuant to the Health in Tech Equity Incentive Plan. Fifty percent (50%) of the shares of restricted stock granted to the reporting person shall vest in equal monthly installments over a twelve (12) month period commencing on the date that the first of two specified programs being developed by the Company is successfully launched and fully operational in the marketplace, and the remaining fifty percent (50%) shall vest in equal monthly installments over a twelve (12) month period commencing on the date that the other specified program being developed by the Company is successfully launched and fully operational in the marketplace.
2. Includes 71,434 shares of Class A Common Stock and 22,105 shares of restricted stock. Excludes 165,085 options to purchase shares of Class A Common Stock.
/s/ (Jonathan) Del Lockett 08/19/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Jonathan Del Lockett report on Form 4 for HIT?

He reported a grant of 7,000 restricted shares of Class A common stock on 08/15/2025 under the Health in Tech Equity Incentive Plan.

How do the restricted shares vest for the HIT grant?

50% of the restricted shares vest in equal monthly installments over 12 months after the first specified program is launched and operational; the remaining 50% vest similarly after the second specified program is launched and operational.

How many shares does Mr. Lockett beneficially own after the transaction?

The filing reports 93,539 shares beneficially owned following the transaction, consisting of 71,434 Class A shares and 22,105 restricted shares.

Are there other equity instruments held by the reporting person?

Yes. The filing states the reporting person holds 165,085 options to purchase Class A common stock, which are excluded from the reported beneficial ownership figure.

When was the Form 4 signed and filed?

The signature on the Form 4 is dated 08/19/2025 and the reported transaction date is 08/15/2025.
Health In Tech, Inc.

NASDAQ:HIT

HIT Rankings

HIT Latest News

HIT Latest SEC Filings

HIT Stock Data

186.08M
13.35M
70.13%
0.86%
0.26%
Software - Application
Insurance Agents, Brokers & Service
Link
United States
STUART